Want to see JP:4527 full AI Analyst Report?
Top Page
Rohto Pharmaceutical Co
(4527)
Select Model
Select Model
Rating:78Outperform
Price Target:
¥3,545.00
▲(16.04% Upside)
Action:Reiterated
Date:08/17/26
The score is driven primarily by strong underlying fundamentals (robust multi-year revenue growth and solid profitability) with some caution from recent margin compression and choppier cash-flow conversion. Technicals are notably positive with strong trend and momentum, while valuation is reasonable but not compelling at a ~19x P/E and ~1.6% yield.
Positive Factors
Revenue Growth
The near-doubling of revenue over five years indicates durable brand demand, effective retail and pharmacy distribution, and successful expansion across healthcare and personal-care categories.
Negative Factors
Margin Compression
Persistent margin erosion suggests higher input, labor, promotion, or product-mix costs are absorbing part of the benefit from growth, potentially limiting earnings expansion unless operating efficiency improves.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The near-doubling of revenue over five years indicates durable brand demand, effective retail and pharmacy distribution, and successful expansion across healthcare and personal-care categories.
Read all positive factors
Rohto Pharmaceutical Co (4527) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥625.20B
Dividend Yield1.86%
Average Volume (3M)973.56K
Price to Earnings (P/E)18.4
Beta (1Y)0.53
Revenue Growth9.67%
EPS Growth-2.92%
CountryJP
Employees9,292
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)146.61
Shares Outstanding236,178,310
10 Day Avg. Volume1,115,680
30 Day Avg. Volume973,556
Financial Highlights & Ratios
PEG Ratio1.40
Price to Book (P/B)1.80
Price to Sales (P/S)1.58
P/FCF Ratio14.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,950.00Price Target Upside-3.44% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)159.62
Revenue Forecast (FY)¥371.03B
Rohto Pharmaceutical Co Business Overview & Revenue Model
Company Description
Established in Osaka, Japan, in 1899, Rohto Pharmaceutical Co.,Ltd. is a global entity engaged in the development, manufacturing, and marketing of a diverse array of pharmaceutical goods, beauty products, and nutritional supplements. Their compreh...
How the Company Makes Money
Rohto Pharmaceutical makes money primarily by selling branded healthcare and personal care products that it manufactures (or outsources under controlled specifications) and distributes through wholesalers, drugstores/pharmacies, mass retailers, an...
Rohto Pharmaceutical Co Financial Statement Overview
Summary
Income Statement
83
Very Positive
Balance Sheet
79
Positive
Cash Flow
72
Positive
| Breakdown | TTM | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 353.38B | 343.73B | 308.63B | 270.84B | 238.66B | 199.65B |
| Gross Profit | 196.35B | 182.96B | 169.46B | 154.93B | 135.13B | 114.10B |
| EBITDA | 64.17B | 65.48B | 56.42B | 50.40B | 42.34B | 35.81B |
| Net Income | 33.13B | 34.25B | 31.00B | 30.94B | 26.38B | 21.13B |
Balance Sheet | ||||||
| Total Assets | 487.15B | 485.77B | 421.88B | 346.18B | 309.68B | 274.88B |
| Cash, Cash Equivalents and Short-Term Investments | 84.77B | 86.82B | 77.16B | 89.21B | 79.95B | 72.79B |
| Total Debt | 58.10B | 60.24B | 61.23B | 12.81B | 12.88B | 21.72B |
| Total Liabilities | 158.69B | 165.59B | 150.43B | 99.14B | 94.60B | 90.88B |
| Stockholders Equity | 309.49B | 301.83B | 260.10B | 246.33B | 209.57B | 178.40B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 36.29B | 27.84B | 26.27B | 22.45B | 16.98B |
| Operating Cash Flow | 0.00 | 47.79B | 36.92B | 34.24B | 30.92B | 27.25B |
| Investing Cash Flow | 0.00 | -29.78B | -57.55B | -16.32B | -13.18B | -16.41B |
| Financing Cash Flow | 0.00 | -11.85B | 3.70B | -13.78B | -16.20B | 3.47B |
Rohto Pharmaceutical Co Technical Analysis
Neutral
3055.00
Price Trends
2764.65
Negative
2576.57
Positive
2506.63
Positive
Market Momentum
-22.59
Positive
39.39
Neutral
17.31
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4527, the sentiment is Neutral. The current price of 3055 is above the 20-day moving average (MA) of 2776.41, above the 50-day MA of 2764.65, and above the 200-day MA of 2506.63, indicating a neutral trend. The MACD of -22.59 indicates Positive momentum. The RSI at 39.39 is Neutral, neither overbought nor oversold. The STOCH value of 17.31 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4527.
Rohto Pharmaceutical Co Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ¥625.20B | 18.37 | 11.29% | 1.86% | 9.67% | -2.92% | |
77 Outperform | ¥3.22T | 23.90 | 12.71% | 2.18% | 6.19% | 21.69% | |
76 Outperform | ¥479.97B | 16.98 | 8.98% | 1.64% | 6.21% | 37.97% | |
68 Neutral | ¥314.57B | 22.92 | 4.90% | 2.54% | 3.22% | 358.24% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
61 Neutral | ¥536.79B | 330.96 | 0.77% | 1.45% | 3.71% | -86.23% | |
58 Neutral | ¥1.31T | -63.98 | ― | 1.52% | 4.96% | -1485.59% |
* Consumer Defensive Sector Average
JP:4527
Rohto Pharmaceutical Co
2,693.00
319.89
13.48%
JP:4452
Kao
3,557.00
520.89
17.16%
JP:4967
Kobayashi Pharmaceutical Co
7,238.00
2,112.24
41.21%
JP:4922
Kose
5,514.00
-239.90
-4.17%
JP:4912
Lion
1,768.50
262.67
17.44%
JP:4911
Shiseido Company,Limited
3,286.00
727.85
28.45%
Rohto Pharmaceutical Co Corporate Events
Rohto Pharmaceutical Lifts Full-Year Earnings Forecast on Strong Overseas Demand
Aug 6, 2026
Rohto Pharmaceutical has raised its consolidated earnings forecast for the fiscal year ending March 31, 2027, reflecting stronger-than-expected performance in its Asia, Japan and Europe segments. The company now expects higher net sales, operating...
Rohto Pharmaceutical Delivers Q1 Sales Growth and Lifts Dividend Outlook
Aug 6, 2026
Rohto Pharmaceutical reported first-quarter consolidated net sales of ¥91.6 billion, up 11.8% year on year, with operating income rising 16.8% to ¥13.7 billion. Despite this growth, ordinary income and profit attributable to owners of pa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.